Editas Medicine Inc. (EDIT)

EDIT trades at $2.69, 7.6% above the near-term max pain of $2.5 expiring Sep 19, 2025 (7 days). Expect downward pressure as dealers benefit from price declining toward max pain. Max pain is rising across expirations ($1-$2.5), reflecting growing call interest at higher strikes. Key magnetic zone at 1 where 2 expirations converge. High dispersion in max pain levels suggests competing forces and potential volatility.

Max pain for EDIT shows an upward trend from 1 to 2.5, suggesting bullish positioning in longer-dated options. The 83% spread signals divergent expectations across timeframes. Most levels below 2.69 may cap rallies. Weekly expirations influence price 2-3 days before expiry; monthlies throughout their final week.